The 18MWT effectively predicts disease severity and clinical outcomes in PAH, complementing the 6MWT by focusing on exercise speed. Significant correlations exist between 18MWT results and WHO ...
Adding WINREVAIR to background PAH therapy improved exercise capacity and WHO functional class (FC), and reduced the risk of clinical worsening events, including hospitalization for PAH, lung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback